News & Events

IMPEL NEUROPHARMA PRESENTS DATA FROM INP104 CLINICAL PROGRAM IN ACUTE MIGRAINE AT THE 2020 AMERICAN HEADACHE SOCIETY (AHS) VIRTUAL ANNUAL SCIENTIFIC MEETING

Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company’s Pivotal Phase 3 Study of INP104 for…

IMPEL NEUROPHARMA ANNOUNCES PRIMARY OBJECTIVES MET IN PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE

Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes…

Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams’ Role Expanded To Chairman and CEO

SEATTLE, May 5, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of…

2 3 4